Dallas, TX – EAGLE OIL HOLDING COMPANY INCORPORATED (OTC: EGOH) "Up 57.58% in morning trading"
Eagle Oil (EGOH) is an independent, growth-oriented energy company engaged in the exploration and production of oil through the development of a repeatable, low geological risk, high potential project in the active East Texas oil and gas region. The Company owns a 78% working interest in 173 wells on its 927 acres located in the Historic Woodbine Oil Field. The Company's goal is to recondition and restore production at all of its wells. Engineering reports show that Eagle Oil's East Texas field contains over 12,000,000 barrels of recoverable oil.
BIOMIMETIC THERAPEUTICS INCORPORATED (NASDAQ: BMTI) "Up 12.68% in morning trading"
BioMimetic Therapeutics is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.
FORCE ENERGY CORPORATION (OTCBB: FORC) "Up 18.57% in morning trading"
Force Energy Corporation (FORC) is a Lithium, Rare Earth and Hydrocarbon Exploration and Development Company based in Denver, Colorado. Force Energy plans to explore and develop its Zoro 1 Lithium property located in the Snow Lake area of west-central Manitoba, Canada. Force Energy also maintains a 50% working interest in the Hayter Well, a Hydrocarbon well located in Alberta, Canada.
OXIGENE INCORPORATED (NASDAQ: OXGN) "Up 9.40% in morning trading"
OXiGENE, Inc. develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase Ib and II clinical trials for other solid tumors, including non-small cell lung cancer, platinum resistant ovarian cancer, and head-and-neck cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, an ortho-quinone prodrug, which is in Phase I clinical trial for solid tumors. The company was founded in 1988 and is headquartered in Waltham, Massachusetts.
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily stock alerts go to www.otcpicks.com to sign up.
Disclosure: OTCPicks.com and affiliates have been not been compensated by any of the companies covered in this release.
